Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 307, Issue 4, 2014, Pages

  Platé, Manuela ^a   Lawson, Phillippa J ^a   Hill, Michael R ^a   Quint, Jennifer K ^a   Kumari, Meena ^a   Laurent, Geoffrey J ^a   Wedzicha, Jadwiga A ^a   Chambers, Rachel C ^a   Hurst, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

COPD; COPD exacerbation; F2R; PAR 1; SNP

Indexed keywords

FIREFLY LUCIFERASE; PROTEINASE ACTIVATED RECEPTOR 1; RENILLA LUCIFERIN 2 MONOOXYGENASE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; F2R GENE; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HELA CELL LINE; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTECTION; PROTEINASE ACTIVATED RECEPTOR 1 GENE; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

COPD; COPD EXACERBATION; F2R; PAR-1; SNP;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONGITUDINAL STUDIES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR, PAR-1;

EID: 84906084215     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00128.2014     Document Type: Article

References (41)

1. Aerts L, Hamelin ME, Rheaume C, Lavigne S, Couture C, Kim W, Susan-Resiga D, Prat A, Seidah NG, Vergnolle N, Riteau B, Boivin G. Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model. PloS One 8: e72529, 2013.
2. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 41: 181-185, 2002.
3. Atzori L, Lucattelli M, Scotton CJ, Laurent GJ, Bartalesi B, De Cunto G, Lunghi B, Chambers RC, Lungarella G. Absence of proteinaseactivated receptor-1 signaling in mice confers protection from fMLPinduced goblet cell metaplasia. Am J Respir Cell Mol Biol 41: 680-687, 2009.
4. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 55: 114-120, 2000.
5. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313, 2005.
6. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 153, Suppl 1: S367-S378, 2008.
7. Chambers RC, Scotton CJ. Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc 9: 96-101, 2012.
8. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, Lange C, Won S, Murphy JR, Beaty TH, Regan EA, Make BJ, Hokanson JE, Crapo JD, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Pillai SG, Silverman EK. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet 42: 200-202, 2010.
9. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 379: 1341-1351, 2012.
10. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, Litonjua A, Bueno R, Pillai SG, Lomas DA, Sparrow D, Shapiro SD, Criner GJ, Kim HP, Chen Z, Choi AM, Reilly J, Silverman EK. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am J Hum Genet 85: 493-502, 2009.
11. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852, 2002.
12. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 61: 164-168, 2006.
13. 2 from contingency tables, and the calculation of P. J R Stat Soc 85: 87-94, 1922.
14. Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, early onset COPD. Eur Respir J 30: 1124-1130, 2007.
15. Gigante B, Vikstrom M, Meuzelaar LS, Chernogubova E, Silveira A, Hooft FV, Hamsten A, de Faire U. Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels. Thromb Haemost 101: 943-953, 2009.
16. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, Stricker BH, O'Connor GT, London SJ. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 42: 45-52, 2010.
17. Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax 69: 609-615, 2014.
18. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138, 2010.
19. Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med 7: 40, 2009.
20. Jankowski M, Undas A, Kaczmarek P, Butenas S. Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation. Thromb Res 127: 242-246, 2011.
21. Kager LM, Wiersinga WJ, Roelofs JJ, van 't Veer C, van der Poll T. Deficiency of protease-activated receptor-1 limits bacterial dissemination during severe Gram-negative sepsis (melioidosis). Microbes Infect 16: 171-174, 2014.
22. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A. 'Role reversal' for the receptor PAR1 in sepsisinduced vascular damage. Nat Immunol 8: 1303-1312, 2007.
23. Marmot M, Brunner E. Cohort Profile: the Whitehall II study. Int J Epidemiol 34: 251-256, 2005.
24. Martinelli A, Knapp S, Anstee Q, Worku M, Tommasi A, Zucoloto S, Goldin R, Thursz M. Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis. J Gastroenterol Hepatol 23: 1403-1409, 2008.
25. Mercer PF, Chambers RC. Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta 1832: 1018-1027, 2013.
26. Mercer PF, Williams AE, Scotton CJ, Jose RJ, Sulikowski M, Moffatt JD, Murray LA, Chambers RC. Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation. Am J Respir Cell Mol Biol 50: 144-157, 2014.
27. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84: 579-621, 2004.
28. Park HY, Nabika T, Jang Y, Kim D, Kim HS, Masuda J. Identification of new single-nucleotide polymorphisms in the thrombin receptor gene and their effects on coronary artery diseases in Koreans. Clin Exp Pharmacol Physiol 27: 690-693, 2000.
29. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, Garcha DS, Wedzicha JA, Hurst JR. Cardiovascular risk, myocardial injury and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188: 1091-1099, 2013.
30. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lodrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5: e1000421, 2009.
31. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575, 2007.
32. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J 37: 501-507, 2011.
33. Sakao S, Tatsumi K. The importance of epigenetics in the development of chronic obstructive pulmonary disease. Respirology 16: 1056-1063, 2011.
34. Schouten M, Van't Veer C, Roelofs JJ, Levi M, van der Poll T. Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care 16: R238, 2012.
35. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418-1422, 1998.
36. 1-antitrypsin deficiency. N Engl J Med 360: 2749-2757, 2009.
37. Smith SM, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, Storey RF. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy. Platelets 16: 340-345, 2005.
38. Steptoe A, Breeze E, Banks J, Nazroo J. Cohort profile: The English Longitudinal Study of Ageing. Int J Epidemiol 42: 1640-1648, 2013.
39. Vaidyula VR, Criner GJ, Grabianowski C, Rao AK. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 124: 259-261, 2009.
40. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 84: 210-215, 2000.
41. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76: 887-893, 2005.